Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β-Reference-Cited by-同舟云学术

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β

Published:2021-12-01 Issue:1 Volume:208 Page:169-180
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Silk Jonathan D.^ORCID,Abbott Rachel J. M.^ORCID,Adams Katherine J.,Bennett Alan D.^ORCID,Brett Sara,Cornforth Terri V.^ORCID,Crossland Katherine L.,Figueroa David J.,Jing Junping,O’Connor Caitriona,Pachnio Annette,Patasic Lea,Peredo Carlos E.^ORCID,Quattrini Adriano,Quinn Laura L.,Rust Alistair G.^ORCID,Saini Manoj,Sanderson Joseph P.^ORCID,Steiner Dylan^ORCID,Tavano Barbara,Viswanathan Preetha^ORCID,Wiedermann Guy E.,Wong Ryan,Jakobsen Bent K.,Britten Cedrik M.^ORCID,Gerry Andrew B.,Brewer Joanna E.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference55 articles.

1. Adoptive cellular therapies: the current landscape.;Rohaan;Virchows Arch.,2019

2. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

3. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma

4. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

5. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review;European Journal of Cancer;2024-09

2. Identification of a small molecule for enhancing lentiviral transduction of T cells;Molecular Therapy - Methods & Clinical Development;2023-12

3. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome;Nature Reviews Drug Discovery;2023-10-27

4. PET imaging with [68Ga]-labeled TGFβ-targeting peptide in a mouse PANC-1 tumor model;Frontiers in Oncology;2023-09-15

5. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02);BMC Cancer;2023-09-15